Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - William Blair lowered their Q1 2025 EPS estimates for shares of Larimar Therapeutics in a note issued to investors on Monday, March 24th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0.46) for the quarter, down from their previous forecast of ($0.35). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics' Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.01) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.07) EPS.

Other research analysts also recently issued research reports about the stock. HC Wainwright upped their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Tuesday, March 25th. Guggenheim restated a "buy" rating and issued a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Truist Financial began coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They set a "buy" rating and a $18.00 target price on the stock. Finally, Robert W. Baird decreased their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $20.22.

Remove Ads

Larimar Therapeutics Price Performance

Shares of Larimar Therapeutics stock traded down $0.22 on Thursday, hitting $2.14. 297,093 shares of the company's stock traded hands, compared to its average volume of 643,870. The company has a fifty day moving average of $3.08 and a two-hundred day moving average of $5.09. The company has a market capitalization of $136.70 million, a price-to-earnings ratio of -1.87 and a beta of 0.99. Larimar Therapeutics has a one year low of $2.13 and a one year high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Hedge Funds Weigh In On Larimar Therapeutics

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new position in shares of Larimar Therapeutics in the 4th quarter worth approximately $25,000. Quest Partners LLC lifted its position in Larimar Therapeutics by 171.1% during the third quarter. Quest Partners LLC now owns 9,183 shares of the company's stock valued at $60,000 after purchasing an additional 5,796 shares in the last quarter. Virtu Financial LLC bought a new stake in Larimar Therapeutics during the third quarter valued at about $71,000. Quarry LP increased its position in Larimar Therapeutics by 50.0% in the third quarter. Quarry LP now owns 12,000 shares of the company's stock worth $79,000 after buying an additional 4,000 shares in the last quarter. Finally, Algert Global LLC bought a new position in shares of Larimar Therapeutics in the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 91.92% of the company's stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.